Latest Industry Insights

With growing pressure on labs to reduce waste and improve sustainability, we spoke to the Sustainability Forum at Agilent to learn more about what the company are doing to help their customers achieve their sustainability goals.

Biomarkers hold immense potential for the future of medicine, enabling more efficient and better-targeted treatments. Most coverage of novel biomarkers to date has been focused on how a patient’s genetic signature can indicate their susceptibility to a disease, but there is a world of other biological and environmental information that can impact how patients respond to treatments. In this blog, SCIEX’s Aaron Hudson explains how non-genetic biomarkers have a key role to play in reaching the goal of truly precise medicine.

Cell-Free Technology is taking a unique approach to protein technology with their BioBits initiative, which they say combines the ease of use of a digital design tool with the detailed scientific validation provided by a CRO. We catch up with Cell-Free CEO Tom Meany to discuss the new technology.

We spoke to Dr Jonathan Jones from Waters Corporation, to learn more about the new initiative that they and Swansea University are leading to give students hands-on experience of mass spectrometry.

A clinical trial has been launched to identify urine-based biomarkers which indicate lung flare-ups in cystic fibrosis. Researchers believe point-of-care monitoring will help people get treatment faster, improve patient outcomes and reduce healthcare costs.

New tools are enabling researchers to explore individual cells with unprecedented clarity, allowing RNA and protein expression levels to be simultaneously analyzed. In this blog, Brian Lilhanand, Global Platform Leader, Single Cell Multiomics, at BD, discusses how BD’s new AbSeq Assay can provide this targeted profiling and benefit immunology researchers.

Following the recent FDA approval of a procalcitonin assay, we spoke with a representative from Fujirebio Diagnostics, Inc. to learn how measuring this important biomarker will improve the healthcare landscape.

During this year’s AACR Annual Meeting we spoke to Dr. Delphine Lissa and Dr. Ana Robles from the National Cancer Institute to learn more about the team’s most recent study on the use of two specific biomarkers for risk stratification of stage I lung cancer patients.

Understanding the proteome is a fundamental challenge of biology. Here, Bruker Daltonics' Gary Kruppa and Scarlet Koch outline a new method, Parallel Accumulation Serial Fragmentation (PASEF) that offers faster, more sensitive and more robust proteome analysis, giving scientists the potential to discover low-level, biologically significant proteins and validate them in research.

As the research landscape changes, the standards of data integrity that guide research must also change. New data tools, systems and formats provide pitfalls and opportunities for advancing the cause of data integrity. In this blog, we discuss integrity in modern research with John Sadler, Vice President and General Manager of Agilent’s Software & Informatics Division.